Last edition
News about "GLP-1 receptor agonists "
The rise of GLP-1 therapies has transformed diabetes and obesity treatment. Following semaglutide patent expiry in India in March 2026, multiple companies entered the market simultaneously. Pharma Industrial India spoke with industry leaders about the opportunities, challenges, and future of this rapidly evolving therapeutic segment.
GLP-1 Receptor Agonists | 26/06/2026 | By Akanki
Chiesi Presents New Metreleptin Data and Patient Care Insights at ENDO 2026
Chiesi Global Rare Diseases presented five new studies at ENDO 2026, highlighting advances in metreleptin therapy for lipodystrophy, potential combination treatments, and the urgent need to address mental health challenges and care gaps among patients with the rare disorder.
GLP-1 Receptor Agonists | 20/06/2026 | By News Bureau
PrecisionLife and Ovation Partner to Launch GLP-1 stratification LDT and GLP-1 DNA Test in H2 2026
PrecisionLife and Ovation partner to launch GLP-1 stratification LDT and consumer DNA test in 2026, with early data showing distinct genetic markers for weight loss and glycemic control.
GLP-1 Receptor Agonists | 16/04/2026 | By News Bureau
Yao Pharma and Pfizer Sign Exclusive Collaboration Deal
Yao Pharma has entered into an exclusive global licensing agreement with Pfizer, granting rights to develop, manufacture, and commercialise its oral small-molecule GLP-1 receptor agonists, including lead candidate YP05002. The partnership aims to advance next-generation metabolic therapies with worldwide reach.
GLP-1 Receptor Agonists | 10/12/2025 | By Akanki | 143
BioMed X and Novo Nordisk Partner to Advance Oral Peptide Drug Delivery
BioMed X and Novo Nordisk’s partnership aims to address one of the most critical challenges in modern drug development: the efficient oral delivery of therapeutic peptides.
GLP-1 Receptor Agonists | 21/08/2025 | By Dineshwori | 677
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy